GR1901

GR1901 is a bispecific monoclonal antibody developed by Chongqing Zhixiang Jintai Biopharmaceutical (Genrix Bio) for the treatment of acute myeloid leukaemia (AML). It functions as a T-cell engager, designed with dual specificity for CD3, a component of the T-cell receptor complex, and CD123 (interleukin-3 receptor alpha chain), which is highly expressed on AML blasts and leukemic stem cells. By simultaneously binding to both targets, GR1901 facilitates the recruitment of cytotoxic T cells to the proximity of CD123-expressing malignant cells, leading to the formation of an immunological synapse, T-cell activation, and subsequent perforin/granzyme-mediated lysis of the tumor cells. The drug is currently in early-stage clinical development to evaluate its safety and therapeutic potential in patients with relapsed or refractory AML.

Other names

CD3 x CD123 bispecific antibodyCD-3 x CD123 bispecific antibodyCD 3 x CD123 bispecific antibodyGenrix GR1901